Singaporean Biotech Startup ImmunoScape Raises US$11M

ImmunoScape is currently collaborating with Arcturus Therapeutics which began human trials of potential COVID-19 vaccine yesterday

Singapore-based biotech startup ImmunoScape announced in a press release today that it has raised US$11 million (SG$14.8 million) in an equity financing round led by U.S.-based Anzu Partners, with participation from the University of Tokyo Edge Capital (UTEC) in Japan, and NPR Holdings in Indonesia.

The startup will use the fresh funds to hire additional personnel, including immunologists, bioinformaticians and specialists, for its laboratory at Singapore-based research and development hub Biopolis, Co-founder and CEO Choon Peng Ng told The Straits Times.

Peng also said that the startup is looking to expand into key markets such as the U.S. and Japan, and is building a business development team and lab in the U.S. as well.

ImmunoScape provides insights into the human immune system. Its immune profiling platform provides deep insights into the T-cells of the human immune system. The company is currently engaged in COVID-19 related projects across three continents, according to the press release.

The startup hopes to eventually use machine learning and artificial intelligence to uncover deeper insights into the human immune system.

“There is an urgent need to understand how the T-cell immune response contributes to COVID-19 immunity and can be leveraged for vaccine design,” said ImmunoScape Co-founder and COO Dr Alessandra Nardin.

“In global collaborations with Massachusetts General Hospital, University of Parma (Italy), and Duke-NUS, we are evaluating COVID-19 patients and recovered individuals,” he continued. “We are building a large data set on human T-cell response to COVID-19, in an effort to develop new therapies and better vaccines with our partners.”

ImmunoScape is also collaborating with several vaccine development companies, including San Diego-based Arcturus which is running clinical trials in Singapore, and began human trials of potential COVID-19 vaccine yesterday.

“As a Singapore-based firm supported by the Agency for Science Technology and Research (ASTAR), our team has deep experience assessing T-cell immune response to dengue, hepatitis B, and other viruses,” Ng said. Ng was formerly a senior executive at ASTAR.

“It was clear that we must provide deep support to COVID-19 vaccine development in this global crisis,” he added.

ImmunoScape’s technology was based on work that began at Stanford University, and continued at A*STAR, where the company was established in 2017.

The company aspires to continue its efforts in enabling advanced immunotherapies for cancer, an area where its scientific track record is strong. The startup focuses on immuno-oncology research which aims at developing cancer treatments using the body’s immune system.

ImmunoScape has received support from ASTAR and its commercialization arm Accelerate, as well as Enterprise Singapore.

“In 2019 we co-authored a paper together with collaborators at Genentech illustrating the role of our technology in evaluating checkpoint blockade immunotherapies,” said Nardin.

“The interest in those insights attracted global attention and encouraged us to seek financing to expand further into the U.S. market,” he added.

“To deliver on the promise of individualized medicine for cancer, the biopharma industry desperately needs more insight into every patient’s unique immune system. ImmunoScape can deliver this, and we are delighted to support them,” Managing Partner at Anzu Partners, David Michael said.

“ImmunoScape’s technology can guide the development of immunotherapies, as the company has shown in major scientific journals. Now they are bringing these insights and capabilities to major biopharma clients globally,” Partner at UTEC, Dr Naonori Kurokawa said.

Header image by National Cancer Institute on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email
Monika Ghosh
Monika Ghosh is a Staff Writer at Jumpstart

RELATED POSTS

Squid Game

Squid Game and Its Lessons on Entrepreneurship

With the massive media buzz the South Korean series “Squid Game” has been getting, you would have to live under a rock to not know about it. It is so popular that a South Korean broadband firm has sued Netflix over the surge in network traffic.

What Is Biotechnology

What Is Biotechnology and How to Start a Biotech Company?

To say that Covid has been a biological nightmare for the world is an understatement. In a bid to wake up from it, companies and investors have turned their attention to science, medicine and innovation—or simply, biotechnology. With vaccines and cures becoming the need of the hour, BioTech rose like never before.

Netflix

Netflix Forays into Video Games with Night School Studio Acquisition

On September 28, 2021, streaming service Netflix announced its first game-related acquisition: Night School Studio. The studio is best known for its game “Oxenfree”, which is a supernatural teen thriller. In a bid to diversify its offerings, Netflix has also released five mobile-friendly video games in Europe (i.e. Spain, Italy and Poland).

Chloe NFT

Side-eyeing Chloe NFT Sold for US$76,377.50

In 2013, the then two-year-old Chloe Clems went viral as her hilarious side-eyeing expression made her into a beloved internet meme. In her meme avatar, little Chloe has ruled over the hearts of many a Twitter and Reddit enthusiast and has been dubbed the “Patron saint of Tumblr” by Buzzfeed.

What Are the Threats of Using Social Media

What Are the Threats of Using Social Media?

Social media has become a part of our everyday lives. As of September 2021, the largest social media platform Facebook has over 2.89 billion active users monthly. With people across the world relying heavily on social media platforms, it is expected that some of them would exploit these platforms for negative purposes as well.

Maker in China Fueling Hong Kong’s Startup Spirit

Maker in China: Fueling Hong Kong’s Startup Spirit

On September 17, 2021, the “Maker in China” SME Innovation and Entrepreneurship Global Contest 2021 Grand Final was held in Guangzhou, China. MAD Gaze, a Cyberport incubatee specializing in augmented reality smart glasses, was declared the winner of the championship.